Compare Quest Diagnostics Inc (DGX) vs Oklo Inc (OKLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Oklo Inc — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while Oklo Inc trades at $34.7 (market cap $6.43B). The key difference: Quest Diagnostics Inc is far larger — about 4× Oklo Inc's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Oklo Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Oklo Inc for 32 Days on average.
| DGX | OKLO | |
|---|---|---|
Market Cap | $25.48B | $6.43B |
Volume | 941,866 | 16,238,368 |
Sector | Health | Utilities |
52-Week High | $247.45 | $174.14 |
52-Week Low | $173.49 | $34.57 |
Typical Hold Time | 56 Days | 32 Days |
Enterprise Value | $31.23B | $3.97B |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.97, up 1.75% today, with a technical bias leaning bearish despite recent earnings beats. Revenue grew to $11.04B in 2025, with net income reaching $992M, though profit margins have moderated. Analyst consensus is a $250 price target with a mixed buy/hold sentiment. Recent news highlights growth in consumer testing and partnerships, alongside concerns over potential Medicare reimbursement cuts.
The outlook balances solid fundamentals and growth initiatives against regulatory risks. Upside potential exists from continued operational execution and new ventures like the Apple Health app integration, but investors face headwinds from reimbursement uncertainty and a high debt load. The stock's valuation appears reasonable relative to peers, supporting a cautious but opportunistic view.
OKLO trades at $34.70, down 5.76% in the last 24 hours, with a bearish technical signal from moving averages. The company reported no revenue in 2025 and a net loss of $105.66 million, with a negative net income margin of -12,625.54%. Recent news highlights competition in the nuclear sector and a $1 billion stock sale, while analyst consensus remains bullish with a $78.63 price target.
Outlook: High growth potential in the nuclear energy market, supported by a strong buy rating from analysts. Risks include significant cash burn, lack of revenue, and execution challenges in commercializing reactor technology. The stock's upside depends on successful project deployment and future revenue generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →
